Conventional synthetic DMARDs (e.g. methotrexate) |
|
|
|
|
Tumor necrosis factor targeted monoclonal antibodies (mAB) (e.g. infliximab) |
|
|
|
|
CD-20 directed monoclonal antibodies (e.g. rituximab) |
|
|
|
|
CTLA-4 targeted therapy (e.g. abatacept) |
|
|
|
|
Il-6 targeted monoclonal antibodies (e.g.tocilizumab) |
|
|
|
|
JAK inhibitors (e.g. tofacitinib) |
|
|
|
|